Streetbeat News

Analyst Ratings

AMZN

Oppenheimer analyst Jason Helfstein has reiterated his 'Outperform' rating on Amazon.com (NASDAQ:AMZN), maintaining a price target of $170.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:22 pm

PLRX

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meeting® 2023. Bexotegrast is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis (IPF) and PSC. The company is pleased with the positive interim results and looks forward to further investigation of bexotegrast, including 12 week data from the 320 mg dose in the first quarter of 2024 and 24 week safety data in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:22 pm

AUMN

GFI

METC

The article identifies three overbought stocks in the materials sector: Ramaco Resources, Inc. (NASDAQ:METC), Gold Fields Limited (NYSE:GFI), and Golden Minerals Company (NYSE:AUMN). Overbought stocks are typically considered for short selling due to their overvalued status. The RSI values for these stocks are above 70, indicating they are overbought.

Portfolio Pulse from Lisa Levin

October 19, 2023 | 12:21 pm

GNRC

JP Morgan analyst Mark Strouse has maintained an Overweight rating on Generac Hldgs (NYSE:GNRC) but lowered the price target from $179 to $164.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:19 pm

SRRK

Scholar Rock (NASDAQ:SRRK), a Phase 3 clinical-stage biopharmaceutical company, announced it will present clinical and biomarker data from the Phase 1 DRAGON trial at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The trial involves patients with advanced solid tumors treated with SRK-181, a selective latent TGFβ1 inhibitor. The company aims to establish the proof of mechanism of SRK-181, which has the potential to transform cancer immunotherapy by overcoming resistance to checkpoint inhibitor therapy.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:18 pm

OKE

Raymond James analyst Justin Jenkins has maintained an 'Outperform' rating on ONEOK (NYSE:OKE) and raised the price target from $78 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:18 pm

HESM

Raymond James analyst JR Weston maintains an Outperform rating on Hess Midstream (NYSE:HESM) and raises the price target from $35 to $38.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:16 pm

EE

Raymond James analyst Justin Jenkins has maintained an 'Outperform' rating on Excelerate Energy (NYSE:EE) but lowered the price target from $27 to $25.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:14 pm

DTM

Raymond James analyst Justin Jenkins has maintained an 'Outperform' rating on DT Midstream (NYSE:DTM) and raised the price target from $55 to $57.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:12 pm

ARIS

Raymond James analyst Justin Jenkins has maintained an 'Outperform' rating on Aris Water Solutions (NYSE:ARIS) but lowered the price target from $14 to $13.

Portfolio Pulse from Benzinga Newsdesk

October 19, 2023 | 12:07 pm